Literature DB >> 1357190

Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

J W Dubay1, S J Roberts, B H Hahn, E Hunter.   

Abstract

Human immunodeficiency virus type 1 contains a transmembrane glycoprotein with an unusually long cytoplasmic domain. To determine the role of this domain in virus replication, a series of single nucleotide changes that result in the insertion of premature termination codons throughout the cytoplasmic domain has been constructed. These mutations delete from 6 to 192 amino acids from the carboxy terminus of gp41 and do not affect the amino acid sequence of the regulatory proteins encoded by rev and tat. The effects of these mutations on glycoprotein biosynthesis and function as well as on virus infectivity have been examined in the context of a glycoprotein expression vector and the viral genome. All of the mutant glycoproteins were synthesized, processed, and transported to the cell surface in a manner similar to that of the wild-type glycoprotein. With the exception of mutants that remove the membrane anchor domain, all of the mutant glycoproteins retained the ability to cause fusion of CD4-bearing cells. However, deletion of more than 19 amino acids from the C terminus of gp41 blocked the ability of mutant virions to infect cells. This defect in virus infectivity appeared to be due at least in part to a failure of the virus to efficiently incorporate the truncated glycoprotein. Similar data were obtained for mutations in two different env genes and two different target cell lines. These results indicate that the cytoplasmic domain of gp41 plays a critical role during virus assembly and entry in the life cycle of human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357190      PMCID: PMC240157     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.

Authors:  T Wilk; T Pfeiffer; V Bosch
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

2.  Alterations to influenza virus hemagglutinin cytoplasmic tail modulate virus infectivity.

Authors:  D A Simpson; R A Lamb
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.

Authors:  P L Earl; S Koenig; B Moss
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes.

Authors:  O K Haffar; D J Dowbenko; P W Berman
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

5.  Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Authors:  M J Mulligan; G V Yamshchikov; G D Ritter; F Gao; M J Jin; C D Nail; C P Spies; B H Hahn; R W Compans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

6.  Effects of mutations within the 3' orf open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity.

Authors:  E Terwilliger; J G Sodroski; C A Rosen; W A Haseltine
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule.

Authors:  J S McDougal; M S Kennedy; J M Sligh; S P Cort; A Mawle; J K Nicholson
Journal:  Science       Date:  1986-01-24       Impact factor: 47.728

8.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein.

Authors:  M Kowalski; L Bergeron; T Dorfman; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more
  148 in total

1.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity.

Authors:  S C Piller; J W Dubay; C A Derdeyn; E Hunter
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity.

Authors:  I Rousso; M B Mixon; B K Chen; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

4.  A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo.

Authors:  S M Kao; E D Miller; L Su
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

5.  Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Authors:  P Zhu; W C Olson; K H Roux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

Authors:  John T West; Sally K Weldon; Stephanie Wyss; Xiaoxu Lin; Qin Yu; Markus Thali; Eric Hunter
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface.

Authors:  M P Grange; V Blot; L Delamarre; I Bouchaert; A Rocca; A Dautry-Varsat; M C Dokhélar
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Positive and negative modulation of virus infectivity and envelope glycoprotein incorporation into virions by amino acid substitutions at the N terminus of the simian immunodeficiency virus matrix protein.

Authors:  Julieta M Manrique; Cristina C P Celma; Eric Hunter; José L Affranchino; Silvia A González
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.